Of interest in 2010: the Anthos 2010 microplate reader

Published: 10-Mar-2010
Manufacturing Analysis

Order before 30 June for free software upgrade

Of interest in 2010: the Anthos 2010 microplate reader
When running routine microplate absorbance assays a robust, easy to use microplate reader is needed. The Biochrom Anthos 2010 Microplate Reader is simply designed to meet researchers needs for a quality instrument at a moderate price.

Four filters are supplied as standard that cover the wavelengths for most common absorbance assays with a colorimetric endpoint, e.g. ELISA, BCA, Bradford and Lowry assays, and additional filters are available.

A choice of software packages enables the user to connect to a PC and run both endpoint and kinetic assays with ease. Results can be printed directly or exported to a spreadsheet for further analysis.

Order the Biochrom Anthos 2010 instrument before the end of June 2010 and the user will receive a free software upgrade to program the plate layout with blanks, standards and controls. This permits the user to perform qualitative analysis on the results or quantify unknown samples using a standard curve eliminating outliers.

The Biochrom Anthos range of high performance microplate instrumentation is manufactured by Biochrom and available worldwide.

For complete specifications on the Biochrom Anthos microplate readers as well as the complete Biochrom product line go to www.Biochrom.co.uk
See more

You may also like

Manufacturing
New generation of microplate readers

New generation of microplate readers

Read more
Biochrom has a new generation of microplate readers, tailored to meet the needs of modern labs

Trending Articles

  1. Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
  2. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  3. Hovione to install first ConsiGma CDC Flex continuous tableting line in US The CDMO is investing $35m in a next-generation continuous tableting line at its 89 Twin Rivers facility in New Jersey, creating an integrated US pathway from spray-dried amorphous solid dispersions to commercial tablet production
  4. GLP-1 news round-up: what's happened in weight loss Lilly's retatrutide posts strong Phase III results, Novo Nordisk pays up to $2.6bn for an oral candidate and nasal and AI-designed approaches advance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II) Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence

You may also like

Manufacturing
New generation of microplate readers

New generation of microplate readers

Biochrom has a new generation of microplate readers, tailored to meet the needs of modern labs
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
Lonza advances aseptic spray drying for high-dose biologics

Lonza advances aseptic spray drying for high-dose biologics

This new technology platform addresses stability, concentration, and delivery challenges in biologics, including new modalities
Manufacturing
Catalent launches ten-month gene-to-drug substance programme for complex biologics

Catalent launches ten-month gene-to-drug substance programme for complex biologics

The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite

The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Subscribe now